Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8WUK0
UPID:
PTPM1_HUMAN
Alternative names:
PTEN-like phosphatase; Phosphoinositide lipid phosphatase; Protein-tyrosine phosphatase mitochondrial 1
Alternative UPACC:
Q8WUK0; E9PAT8; Q7Z557; Q96CR2; Q9BXV8
Background:
Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1, known by alternative names such as PTEN-like phosphatase and Phosphoinositide lipid phosphatase, plays a pivotal role in cellular processes. It dephosphorylates phosphatidylglycerophosphate to phosphatidylglycerol, an essential step in cardiolipin biosynthesis. This mitochondrial-specific phospholipid is crucial for maintaining membrane integrity and organelle activities. Additionally, it exhibits phosphatase activity towards phosphoproteins, significantly impacting ATP production and mitochondrial function.
Therapeutic significance:
Understanding the role of Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 could open doors to potential therapeutic strategies.